JP2004513070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004513070A5 JP2004513070A5 JP2001587753A JP2001587753A JP2004513070A5 JP 2004513070 A5 JP2004513070 A5 JP 2004513070A5 JP 2001587753 A JP2001587753 A JP 2001587753A JP 2001587753 A JP2001587753 A JP 2001587753A JP 2004513070 A5 JP2004513070 A5 JP 2004513070A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- acyl
- use according
- amino acid
- erythro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000002252 acyl group Chemical group 0.000 description 36
- 239000001226 triphosphate Substances 0.000 description 34
- 235000011178 triphosphate Nutrition 0.000 description 34
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 30
- 150000003839 salts Chemical class 0.000 description 29
- 239000008194 pharmaceutical composition Substances 0.000 description 24
- 125000000217 alkyl group Chemical group 0.000 description 21
- AFINAILKDBCXMX-PBHICJAKSA-N (2s,3r)-2-amino-3-hydroxy-n-(4-octylphenyl)butanamide Chemical compound CCCCCCCCC1=CC=C(NC(=O)[C@@H](N)[C@@H](C)O)C=C1 AFINAILKDBCXMX-PBHICJAKSA-N 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 16
- 125000000539 amino acid group Chemical group 0.000 description 16
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 16
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 16
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 16
- 239000001177 diphosphate Substances 0.000 description 12
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 12
- 235000011180 diphosphates Nutrition 0.000 description 12
- 150000004712 monophosphates Chemical class 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 239000004474 valine Substances 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 208000037262 Hepatitis delta Diseases 0.000 description 5
- 241000724709 Hepatitis delta virus Species 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 4
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 4
- CKTSBUTUHBMZGZ-CHKWXVPMSA-N 4-amino-1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 CKTSBUTUHBMZGZ-CHKWXVPMSA-N 0.000 description 3
- 0 CC(*=C(C(I)=CCC[C@]1O[C@@](CO)C(*)C1)I)=O Chemical compound CC(*=C(C(I)=CCC[C@]1O[C@@](CO)C(*)C1)I)=O 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960005311 telbivudine Drugs 0.000 description 3
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 3
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 2
- 229960001997 adefovir Drugs 0.000 description 2
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960004396 famciclovir Drugs 0.000 description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 2
- LLYJISDUHFXOHK-GOCONZMPSA-N ferroptocide Chemical compound C[C@@H]1CC[C@@]23C[C@@H](C(=O)[C@]2([C@@]1([C@@H](C[C@H]([C@@H]3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O LLYJISDUHFXOHK-GOCONZMPSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- -1 lobukavir Chemical compound 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960001179 penciclovir Drugs 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20753800P | 2000-05-26 | 2000-05-26 | |
| PCT/US2001/017301 WO2001091737A2 (en) | 2000-05-26 | 2001-05-29 | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004513070A JP2004513070A (ja) | 2004-04-30 |
| JP2004513070A5 true JP2004513070A5 (enExample) | 2008-08-14 |
Family
ID=22771005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001587753A Pending JP2004513070A (ja) | 2000-05-26 | 2001-05-29 | β−Ｌ−２’−デオキシヌクレオシドを用いたデルタ型肝炎ウイルス感染の処置方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6596700B2 (enExample) |
| EP (1) | EP1292313B1 (enExample) |
| JP (1) | JP2004513070A (enExample) |
| KR (1) | KR100854398B1 (enExample) |
| CN (1) | CN100490818C (enExample) |
| AT (1) | ATE275406T1 (enExample) |
| AU (3) | AU6348401A (enExample) |
| BR (1) | BR0111195A (enExample) |
| CA (1) | CA2410488C (enExample) |
| DE (1) | DE60105424T2 (enExample) |
| EA (1) | EA005890B1 (enExample) |
| ES (1) | ES2227203T3 (enExample) |
| IL (1) | IL153078A0 (enExample) |
| MX (1) | MXPA02011641A (enExample) |
| TR (1) | TR200402565T4 (enExample) |
| WO (1) | WO2001091737A2 (enExample) |
| ZA (2) | ZA200210100B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA986614B (en) * | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| KR100691737B1 (ko) * | 1998-08-10 | 2007-03-12 | 이데닉스(케이만)리미티드 | Ｂ형 간염의 치료용 β-Ｌ-2'-데옥시-뉴클레오시드 |
| US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
| AU2001245575A1 (en) * | 2000-03-09 | 2001-09-17 | Videoshare, Inc. | Sharing a streaming video |
| KR100974917B1 (ko) | 2000-04-13 | 2010-08-09 | 파마셋 인코포레이티드 | 간염 바이러스 감염 치료를 위한 3'- 또는2'-하이드록시메틸 치환된 뉴클레오시드 유도체 |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| AU2001272923A1 (en) | 2000-05-26 | 2001-12-11 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
| US6787526B1 (en) * | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
| EP1411954B1 (en) * | 2000-10-18 | 2010-12-15 | Pharmasset, Inc. | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| CA2490191C (en) * | 2002-06-28 | 2010-08-03 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections |
| US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| AP2005003211A0 (en) * | 2002-06-28 | 2005-03-31 | Idenix Cayman Ltd | 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections. |
| KR20050035194A (ko) * | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘 |
| CN100536853C (zh) * | 2002-09-13 | 2009-09-09 | 艾登尼科斯（开曼）有限公司 | β-L-2′-脱氧核苷用于治疗抗性HBV株以及联合治疗 |
| WO2004041837A1 (en) * | 2002-10-31 | 2004-05-21 | Metabasis Therapeutics, Inc. | Novel cytarabine monophosphate prodrugs |
| CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′－支链核苷和黄病毒突变 |
| CN1303089C (zh) * | 2002-11-19 | 2007-03-07 | 天津药物研究院 | 阿德福韦酯结晶形态及其制备方法 |
| CN1330373C (zh) * | 2002-12-02 | 2007-08-08 | 美德（江西）生物科技有限公司 | 含alfa－干扰素，阿地福韦和二脱氧氟硫代胞嘧啶的药物组合物 |
| KR20050109918A (ko) | 2002-12-12 | 2005-11-22 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드의 제조 방법 |
| KR100883703B1 (ko) | 2003-05-30 | 2009-02-12 | 파마셋 인코포레이티드 | 변형 불소화 뉴클레오시드 유사체 |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| EP3109244B1 (en) | 2004-09-14 | 2019-03-06 | Gilead Pharmasset LLC | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| EP1893211B1 (en) | 2005-06-17 | 2011-09-14 | Novartis AG | Use of sanglifehrin in hcv |
| WO2007075876A2 (en) | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| GB0623493D0 (en) * | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
| US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| CN102753563A (zh) | 2008-12-23 | 2012-10-24 | 吉利德制药有限责任公司 | 核苷类似物 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| EA026341B9 (ru) | 2010-03-31 | 2021-12-27 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Кристаллическая форма нуклеозидфосфорамидата |
| SG188497A1 (en) | 2010-09-22 | 2013-05-31 | Alios Biopharma Inc | Substituted nucleotide analogs |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| EP2648701B1 (en) * | 2010-12-10 | 2023-05-24 | Sigmapharm Laboratories, LLC | Highly stable compositions of adefovir dipivoxil |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
| WO2013142124A1 (en) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| HK1203356A1 (en) | 2012-03-22 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Pharmaceutical combinations comprising a thionucleotide analog |
| UA118256C2 (uk) | 2013-01-31 | 2018-12-26 | Гіліад Фармассет Елелсі | Комбінований склад двох противірусних сполук |
| MX359656B (es) * | 2013-07-31 | 2018-10-05 | Merck Patent Gmbh | Derivados de oxoquinazolinil-butanamida. |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| EP3623364A1 (en) | 2014-02-13 | 2020-03-18 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| RU2721492C2 (ru) | 2015-06-17 | 2020-05-19 | Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк | Дезоксинуклеозидная терапия заболеваний, вызванных несбалансированными пулами нуклеотидов, в том числе синдромов истощения митохондриальной днк |
| EP3344642A1 (en) | 2015-09-02 | 2018-07-11 | AbbVie Inc. | Anti-viral tetrahydrofurane derivatives |
| CN108264524A (zh) * | 2016-12-31 | 2018-07-10 | 正大天晴药业集团股份有限公司 | 恩曲他滨膦酸酯化合物 |
| RU2644156C1 (ru) | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
| EP4512475A3 (en) | 2017-07-11 | 2025-05-14 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| RU2662161C1 (ru) * | 2017-08-11 | 2018-07-24 | Васильевич Иващенко Александр | Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита |
| US11970482B2 (en) | 2018-01-09 | 2024-04-30 | Ligand Pharmaceuticals Inc. | Acetal compounds and therapeutic uses thereof |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| JP7664287B2 (ja) | 2020-05-29 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | レムデシビル治療方法 |
| AU2021296841B2 (en) | 2020-06-24 | 2025-01-23 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| KR20250111239A (ko) | 2020-08-27 | 2025-07-22 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염 치료를 위한 화합물 및 방법 |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| CA3244278A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
| JP3693357B2 (ja) * | 1993-04-09 | 2005-09-07 | 峯郎 実吉 | 逆転写酵素阻害剤 |
| WO1996011204A1 (de) | 1994-10-07 | 1996-04-18 | Max-Delbrück-Centrum für Molekulare Medizin | NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG |
| KR100691737B1 (ko) * | 1998-08-10 | 2007-03-12 | 이데닉스(케이만)리미티드 | Ｂ형 간염의 치료용 β-Ｌ-2'-데옥시-뉴클레오시드 |
-
2001
- 2001-05-29 JP JP2001587753A patent/JP2004513070A/ja active Pending
- 2001-05-29 EA EA200201263A patent/EA005890B1/ru not_active IP Right Cessation
- 2001-05-29 EP EP01937785A patent/EP1292313B1/en not_active Expired - Lifetime
- 2001-05-29 MX MXPA02011641A patent/MXPA02011641A/es active IP Right Grant
- 2001-05-29 AT AT01937785T patent/ATE275406T1/de not_active IP Right Cessation
- 2001-05-29 US US09/867,110 patent/US6596700B2/en not_active Expired - Fee Related
- 2001-05-29 IL IL15307801A patent/IL153078A0/xx not_active IP Right Cessation
- 2001-05-29 CA CA002410488A patent/CA2410488C/en not_active Expired - Fee Related
- 2001-05-29 AU AU6348401A patent/AU6348401A/xx active Pending
- 2001-05-29 TR TR2004/02565T patent/TR200402565T4/xx unknown
- 2001-05-29 WO PCT/US2001/017301 patent/WO2001091737A2/en not_active Ceased
- 2001-05-29 BR BR0111195-7A patent/BR0111195A/pt not_active Application Discontinuation
- 2001-05-29 ES ES01937785T patent/ES2227203T3/es not_active Expired - Lifetime
- 2001-05-29 KR KR1020027015985A patent/KR100854398B1/ko not_active Expired - Fee Related
- 2001-05-29 DE DE60105424T patent/DE60105424T2/de not_active Expired - Fee Related
- 2001-05-29 CN CNB018134297A patent/CN100490818C/zh not_active Expired - Fee Related
- 2001-05-29 AU AU2001263484A patent/AU2001263484B2/en not_active Ceased
-
2002
- 2002-12-12 ZA ZA200210100A patent/ZA200210100B/en unknown
-
2004
- 2004-06-01 ZA ZA200404304A patent/ZA200404304B/xx unknown
-
2006
- 2006-12-21 AU AU2006252214A patent/AU2006252214A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004513070A5 (enExample) | ||
| RU2006147216A (ru) | Бета-l-2` дезокси-нуклеозиды для лечения гепатита в | |
| JP2006516949A5 (enExample) | ||
| Mahmoud et al. | Antiviral nucleoside and nucleotide analogs: a review | |
| CA2498731A1 (en) | .beta.-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies | |
| Deval | Antimicrobial strategies: inhibition of viral polymerases by 3′-hydroxyl nucleosides | |
| JP2004533401A5 (enExample) | ||
| CA2322008A1 (en) | 2'-fluoronucleosides | |
| CA2502109A1 (en) | 4'-c-substituted-2-haloadenosine derivative | |
| JP2021517132A (ja) | ４’−ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| JP2005015491A5 (enExample) | ||
| JP2005503358A5 (enExample) | ||
| JP2009538829A5 (enExample) | ||
| CA2409613A1 (en) | Methods and compositions for treating hepatitis c virus | |
| JP2008523098A5 (enExample) | ||
| CN102939291A (zh) | 用于病毒感染治疗的具有降低的毒性的膦酸酯 | |
| JPWO2003015798A1 (ja) | 新規なウイルス増殖阻害・殺ウイルス方法および新規なピラジンヌクレオチド・ピラジンヌクレオシド類似体 | |
| Kreemerova | Amino acid ester prodrugs of nucleoside and nucleotide antivirals | |
| CN102137676A (zh) | 抗病毒化合物 | |
| JP2005508297A5 (enExample) | ||
| WO2000016755A3 (en) | Antiviral combinations of lamivudine and adefovir | |
| JP2001335592A5 (enExample) | ||
| Macchi et al. | Phosphonated nucleoside analogues as antiviral agents | |
| RU2001106651A (ru) | Бета-l-2 - дезокси-нуклеотиды для лечения гепатита в | |
| JP2008509110A5 (enExample) |